Takeda Low-Dose TAK-475 Trials to Continue; Lifts Stock (Japan)
This article was originally published in PharmAsia News
Takeda Pharmaceuticals has announced it will continue drug trials of its experimental cholesterol treatment TAK-475. The announcement comes on the heels of a U.S. Food and Drug Administration recommendation that the company stop using high doses of the drug in trials. The decision stemmed from concerns that high doses of the drug may cause liver damage. As a result, the company's stock took a serious downturn, falling 10 percent on Oct. 30. In response, Takeda announced it would remove the 100 mg dose of TAK-475 from trials but continue with the 50 mg dose. Industry insiders say this clarification could put the company's shares back on the rise. (Click here for more - May Require Paid Subscription
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.